QT Imaging (QTI) Q3 2026 earnings review
Medicare approves QT Imaging scans, but war cuts its outlook
QT Imaging, a maker of radiation-free breast scanners, won a key US Medicare payment ruling while war in the Middle East blocked its international shipments. Third-quarter revenue rose 75% to $7.3 million on 15 scanners sold in the US, and the company collected all $7.3 million of those bills in October. However, chief executive Raluca Dinu cut the full-year revenue plan to $34 million because shipping closures in the Strait of Hormuz stopped deliveries to Saudi Arabia and the United Arab Emirates.
| Revenue | $7.3M +75% from a year ago (15 scanners sold) |
|---|---|
| Operating loss | $2.4M $1.7M loss a year ago |
| Full-year revenue outlook | Cut $5M to ~$34M; implies $12.7M in Q4 |
| Medicare outpatient payment | Approved for diagnostic scans starting Jan 1, 2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because a long-term breakthrough in US hospital payment offset the near-term hit from blocked Middle East shipments. Medicare reversed an earlier proposal and approved hospital outpatient payment for diagnostic scans starting in January 2027, which helps the new direct sales team sell to US hospitals as the current US distributor commitment expires. On the negative side, unshipped machines pushed inventory to $11.5 million and widened the operating loss.
The question now is whether direct US hospital sales can replacedistributor minimum commitments while Middle East routes remain closed. Even the reduced full-year plan requires about $12.7 million of fourth-quarter revenue by our math, which is about $4 million more than the scheduled US distributor shipments alone provide. Fourth-quarter shipments and the 2027 order backlog will settle it.
🐂 Bull Case
Medicare Approves Hospital Payment for Diagnostic Scans
QT Imaging makes radiation-free breast scanners that use sound waves instead of X-rays. Until now, the company had only a tracking code for billing, which meant hospitals had no guaranteed Medicare payment when using the machine. On November 4, the Centers for Medicare & Medicaid Services reversed an earlier proposal not to pay and approved separate hospital outpatient payment starting January 1, 2027.
Chief executive Raluca Dinu said the ruling "removes a significant reimbursement uncertainty and strengthens our ability to expand into U.S. hospitals and health systems". The decision pairs with a dedicated billing code that took effect on October 1. However, the company noted that the Medicare payment applies only to medically necessary diagnostic scans and "does not extend to routine breast cancer screening".
What to watch: commercial insurance coverage decisions and direct hospital orders in the first half of 2027. A rise in hospital orders would show that diagnostic Medicare payment is enough for hospitals to buy machines without screening coverage.
Direct Orders and Hospital Contracts Build the Sales Channel
QT Imaging has relied on its US distributor, NXC Imaging, to buy a fixed minimum number of scanners in 2026. Because NXC's contract commitments end this year and the distributor has placed machines slowly with actual clinics, QT Imaging hired its own regional sales leaders to take over US selling in 2027.
This quarter, the company "began receiving direct customer purchase orders" alongside NXC's contracted purchases. NXC also won a group purchasing contract with Premier, giving QT Imaging a faster buying process across Premier's network of nearly 4,400 US hospitals. In the Middle East, its local partner won the first major hospital order in the United Arab Emirates from American Hospital Dubai.
What to watch: the number of direct scanner orders booked for 2027 delivery, disclosed on the fourth-quarter report. That figure will show whether direct hospital sales can replace the 60-scanner NXC minimum commitment that expires in December.
New Factory and Regulatory Approvals Expand Capacity
QT Imaging finished moving into its new 22,000-square-foot headquarters and factory in Petaluma, California during the third quarter. Dinu said the move "doubled our manufacturing capacity" while improving efficiency, and the plant passed its first routine US Food and Drug Administration inspection with zero observations.
On the product and regulatory side, the company won clearance to sell its scanners in Israel and Bahrain and continued clinical studies on dense breasts and cancer treatment monitoring. It also upgraded its image viewer and cloud software, completing the operational setup needed to supply more markets once shipping routes open.
What to watch: fourth-quarter gross margin on the first scanners built inside the Petaluma plant. A higher margin on US shipments would confirm that the lower rent and larger assembly line reduce the cost of making each scanner.
🐻 Bear Case
Middle East Conflict Cuts the Revenue Plan by $5 Million
For three quarters, QT Imaging held to a full-year revenue plan of about $39 million. By our math, hitting that target required shipping 18 to 20 scanners to Middle East distributors in the second half after shipping none in the first half. In the third quarter, the company again shipped all 15 of its scanners in the US "in accordance with minimum order quantities under the Company’s amended NXC Imaging distribution agreement".
Management cut the 2026 revenue outlook to about $34 million, citing the "inability to complete anticipated scanner shipments to distribution partners in Saudi Arabia and the UAE because of ongoing armed conflict and disruptions to shipping routes, including the effective closure of the Strait of Hormuz to commercial traffic". Because international units stayed at zero, third-quarter gross margin remained at 41.3%, down 1.7 percentage points from a year ago and below the 45% full-year target.
What to watch: fourth-quarter revenue against the $12.7 million implied by the revised full-year outlook. Since the scheduled 17 US scanners generate about $8.3 million by our math, hitting the new target still requires about $4.4 million of fourth-quarter revenue from delayed international units or new direct orders.
Inventory Buildup and Higher Overhead Keep Draining Cash
The press release highlights that net loss shrank to $0.3 million from $4.6 million a year ago, calling it a significant improvement. That headline figure includes a $2.4 million non-cash accounting gain from revaluing an earnout liability because performance targets were not met. Excluding warrant and earnout revaluations, the net loss was $2.8 million by our math, and the operating loss widened to $2.4 million from $1.7 million a year ago.
- Total cash and restricted cash: $8.4 million, down from $11.0 million in June
- Inventory: $11.5 million, up from $9.9 million in June and $5.0 million at year-end
- Operating cash outflow: $2.2 million in Q3 by our math, and $10.7 million over nine months
- Operating expenses: $5.5 million, up 58.5% from a year ago on clinical studies and payroll
Unshipped scanners are tying up cash in inventory while research and development rose 1.1 percentage points of revenue to 23.5%. Collecting $7.3 million of third-quarter receivables in October replenished cash after the quarter closed, but ongoing losses keep liquidity tight.
What to watch: inventory and cash balances at year-end. Converting the $11.5 million inventory pile into cash depends on shipping delayed Middle East scanners rather than building more unsold stock.
Risks this quarter didn't answer
Three standing questions about customer usage and 2027 contracts received no figures in the third-quarter release.
- Scanner placements at clinics: QT Imaging records revenue when it ships to NXC, and the release did not disclose how many of NXC's 43 scanners shipped this year are installed at hospitals.
- Post-2026 US distributor commitment: NXC's 60-scanner minimum order ends in Q4, and management announced no contract extension for 2027.
- Cloud software revenue: the release noted improvements to QTI Precision Pathway cloud tools, but gave no subscription revenue figure.
💲 Other KPIs
Uncollected customer bills at the end of September equaled 100% of third-quarter revenue, showing that scanner shipments again took place late in the quarter. However, QT Imaging stated that it collected the entire $7.34 million balance in cash by the end of October, removing collection risk on the third-quarter shipments.
The share count rose 65.5% from 9.60 million a year ago and 7.2% from 14.83 million in the second quarter. The increase reflects the October 2025 private stock placement and the second-quarter 2026 public stock offering that QT Imaging used to fund its operations and repay debt.
Total debt consists of $11.40 million in long-term debt and $3.90 million in notes payable to related parties, unchanged from June. In May, the medical device maker extended its senior loan maturity to March 2029 at a 12% interest rate, which kept third-quarter net interest expense at $0.33 million.
🔮 Guidance
Cut. The revised plan lowers full-year revenue by $5 million, pointing to 80% growth for the year instead of 106% by our math. With $21.3 million recorded in the first nine months, the outlook leaves about $12.7 million for the fourth quarter, up 53% from a year ago. Management cut the plan because war in the Middle East blocked shipments to Saudi Arabia and the UAE.
❓ Key Questions
What fills the $4.4 million gap in fourth-quarter revenue?
By our math, the $34 million outlook requires $12.7 million in Q4. The 17 planned US scanners bring about $8.3 million, leaving $4.4 million (~9 scanners) that must come from delayed Middle East shipments or new direct US orders.
How many NXC scanners are installed at clinics today?
QT Imaging shipped 43 scanners in the first nine months under NXC Imaging's minimum order contract. Knowing how many sit in NXC's warehouse versus scanning patients at clinics will show whether US demand supports 2027 reorders.
How many direct customer purchase orders have been booked?
The company began receiving direct orders in Q3 and gained access to Premier's 4,400-hospital network. Disclosing the unit count and dollar value of direct orders will show whether the new sales team can replace NXC's expiring 60-unit commitment in 2027.
What is the 2027 Medicare payment rate under APC 5522?
CMS assigned diagnostic QTscan exams to Ambulatory Payment Classification 5522 starting January 1, 2027. Sharing the exact dollar payment per scan will show how quickly a US hospital can pay back the ~ $490,000 cost of a scanner.